A large proportion of patients continue to be diagnosed with epilepsy of "unknown etiology", and treating focal epilepsy continues to be done the same way, for the most part, regardless of etiology: antiepileptic medications are tried first, and if those don't work after a few trials, patients are evaluated for a brain surgery. Such an approach would be acceptable in one of two scenarios: 1) if etiology was irrelevant in guiding treatment, or 2) if the differently-treated etiology was so rare, and difficult to detect without costly testing, that one cannot justify spending significant resources to diagnose it. Let's think of autoimmune epilepsy in the context of these two scenarios.
Question 1: Does a diagnosis of autoimmune epilepsy modify a patient's treatment? The evidence supports a "Yes" for an answer.
In the study by Dubey et al. highlighted IMPORTANCE: Autoimmune epilepsy is an underrecognized condition, and its true incidence is unknown. Identifying patients with an underlying autoimmune origin is critical because these patients' condition may remain refractory to conventional antiseizure medications but may respond to immunotherapy. OBJECTIVE: To determine the prevalence of neurological autoantibodies (Abs) among adult patients with epilepsy of unknown etiology. DESIGN, SETTING, AND PARTICIPANTS: Consecutive patients presenting to neurology services with new-onset epilepsy or established epilepsy of unknown etiology were identified. Serum samples were tested for autoimmune encephalitis Abs as well as thyroperoxidase (TPO) and glutamic acid decarboxylase 65 (GAD65) Abs. An antibody prevalence in epilepsy (APE) score based on clinical characteristics was assigned prospectively. Data were collected from June 1, 2015, to June 1, 2016. MAIN OUTCOMES AND MEASURES: Presence of neurological Abs. A score based on clinical characteristics was assigned to estimate the probability of seropositivity prior to antibody test results. Good seizure outcome was estimated on the basis of significant reduction of seizure frequency at the first follow-up or seizure freedom. RESULTS: Of the 127 patients (68 males and 59 females) enrolled in the study, 15 were subsequently excluded after identification of an alternative diagnosis. Serum Abs suggesting a potential autoimmune etiology were detected in 39 (34.8%) cases. More than 1 Ab was detected in 7 patients (6.3%): 3 (2.7%) had TPO-Ab and voltage-gated potassium channel complex (VGKCc) Ab, 2 (1.8%) had GAD65-Ab and VGKCc-Ab, 1 had TPO-Ab and GAD65-Ab, and 1 had anti-Hu Ab and GAD65-Ab. Thirty-two patients (28.6%) had a single Ab marker. Among 112 patients included in the study, 15 (13.4%) had TPO-Ab, 14 (12.5%) had GAD65-Ab, 12 (10.7%) had VGKCc (4 of whom were positive for leucine-rich glioma-inactivated protein 1 [LGI1] Ab), and 4 (3.6%) had N-methyl-D-aspartate receptor (NMDAR) Ab. Even after excluding TPO-Ab and low-titer GAD65-Ab, Abs strongly suggesting an autoimmune cause of epilepsy were seen in 23 patients (20.5%). Certain clinical features, such as autonomic dysfunction, neuropsychiatric changes, viral prodrome, faciobrachial dystonic spells or facial dyskinesias, and mesial temporal sclerosis abnormality on magnetic resonance imaging, correlated with seropositivity. The APE score was a useful tool in predicting positive serologic findings. Patients who were Ab positive were more likely to have good seizure outcome than were patients with epilepsy of unknown etiology (15 of 23 [65.2%] vs 24 of 89 [27.0%]; odds ratio, 4.8; 95% CI, 1.8-12.9; P = .002). In patients who were seropositive, reduction in seizure frequency was associated with use of immunomodulatory therapy. CONCLUSIONS AND RELEVANCE: Among adult patients with epilepsy of unknown etiology, a significant minority had detectable serum Abs suggesting an autoimmune etiology. Certain clinical features (encoded in the APE score) could be used to identify patients with the highest probability of harboring neurological Abs.
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of immunomodulatory therapy. In another recent retrospective study of 50 patients with confirmed autoimmune encephalitis initially presenting with seizures, 36% became seizure-free with immunotherapy alone, 10% became seizure-free with antiepileptic drugs (AED)s alone, and 8% with AEDs after immunotherapy failure 1 . Several other reports similarly support the importance of immunomodulation in achieving an optimal outcome when autoimmune epilepsy is confirmed or strongly suspected 2,3 . The existing challenge though is that once we reach the clinical judgment that "immunomodulation is needed because we suspect autoimmune epilepsy", we don't know exactly how best to proceed. In a recent review 4 , Bien and Holtkamp outline a treatment protocol based on their clinical experience, starting with a first line therapy of intravenous immunoglobulins or high dose oral methylprednisolone with a subsequent taper to a maintenance dose. Escalating to rituximab or cyclophosphamide is recommended in case of no response to methylprednisolone or intravenous immunoglobulin. Albeit helpful, this review acknowledges the dearth of evidence guiding these treatment decisions given the lack of randomized clinical trials or large scale rigorous observational cohort studies specifically designed to answer treatment questions. With growing awareness of autoimmune epilepsy as a clinically relevant entity, and increasing comfort level of epileptologists to use or seek help to use immune therapy, the future should hopefully bring more clarity as the clinical need, patient volumes, and clinical research infrastructure necessary to conduct these studies become more available.
Question 2: is autoimmune epilepsy too rare and costly to detect? The answer to this question is more nuanced.
Let's dissect it. The exact prevalence of autoimmune epilepsy is actually not clearly known. The article at hand puts seropositivity at a prevalence of 35% in consecutive patients presenting with new-onset epilepsy or established epilepsy of unknown etiology. This prevalence drops to about 20% when patients with the less specific thyroperoxidase (TPO) and those with low titers of glutamic acid decarboxylase 65 (GAD65) Abs are excluded. Another recent study by Brenner et.al, conducted in the United Kingdom, reported the presence of neurological antibodies in 46 of 416 adult patients with epilepsy (11%) 5 . This variation in prevalence estimates may be explained by the difference in the cohorts analyzed: in the Dubey study (20%-35%), patients with idiopathic mesial temporal sclerosis or epilepsy of unknown etiology were analyzed, whereas the lower prevalence estimate of 11% was found in a cohort with more lax exclusion criteria (only patients with clear provoked seizures or a progressive neurological disorder were excluded). It seems then, that even though an exact prevalence number still needs to be defined, the true prevalence lies somewhere between 10% and 35%, depending on the pre-test probability in the cohort in question. Either way, the number seems to be too high to ignore from a global epidemiological perspective, but too low to justify indiscriminate costly antibody testing.
Recapitulating then the answers to our two decision-branching questions from earlier, we find that: 1) identifying an autoimmune epilepsy etiology significantly alters treatment and its outcomes, and therefore should be achieved as soon as possible; and 2) the prevalence is not insignificant so it deserves our attention but the issue is that the ideal diagnostic tests (antibody assays) are still too expensive and not widely available. So, what do we do? We try to zoom in on the most efficient approach to identify patients with autoimmune epilepsy. This is exactly what Dubey et al. tried to do through developing an Antibody Prevalence in Epilepsy (APE) score. The APE score combines clinical characteristics (seizure refractoriness, epilepsy duration, associated autonomic symptoms, abnormal movements, associated malignancies), with CSF and imaging findings to produce a score that correlates with seropositivity. This APE score was predictive of seropositivity in a highly selected retrospective cohort of patients who were already suspected to have autoimmune epilepsy 6 , so albeit promising, its true predictive value remains to be prospectively validated. Alternatively, recognizing the limitations due to the high cost and slow processing time of antibody testing, Graus et.al proposed a clinical approach to the diagnosis of autoimmune encephalitis 7 . In a thoroughly detailed position statement, Graus et.al lay out the clinical scenarios that should raise suspicion for autoimmune encephalitis/epilepsy, thereby identifying patients with the highest expected yield for antibody testing, but more importantly, those with a clinical picture that would justify treatment for autoimmune encephalitis even while waiting to receive the results of antibody testing. Such efforts to define autoimmune epilepsy on clinical grounds are even more critical as we recognize that patients may be "seronegative" but still have autoimmune epilepsy, given the lag of our knowledge as we are only starting to scratch the surface of this entity and still have many more pathogenic antibodies to discover [2] [3] [4] 8 .
In an era where the medical or surgical costs of treating drug-resistant epilepsy are sky-rocketing, and the negative implications of a delayed or missed diagnosis of autoimmune epilepsy are so high (drug-resistance, permanent cognitive deficits, etc), more efforts to better identify the patients at risk and better understand the pathophysiological significance of neurological auto-antibodies are needed.
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